<DOC>
	<DOCNO>NCT01654094</DOCNO>
	<brief_summary>The purpose study evaluate P6 Low Adherent Study Dressing relative Standard Care ( SOC , Mafenide Acetate 5 % Solution ) management skin graft burn wound result thermal burn injury .</brief_summary>
	<brief_title>Study Low Adherent Dressing Versus Standard Care Management Skin Grafts Over Thermal Burns</brief_title>
	<detailed_description />
	<mesh_term>Burns</mesh_term>
	<criteria>Patients must thermal burn scald , flame/fire contact hot object . Patients must TBSA burn less equal 50 % . Patients must two nonadjacent study burn site ( i.e. , separate way SOC dress contaminate study dress ) comparable size ( approximately 2 % TBSA ) severity require excision grafting . Patients must undergo excision autografting postburn day ( PBD ) 14 . Patients ' study burn site treat skin graft mesh ratio 3:1 , surgeon 's discretion . Patients expect available assessment study burn site least POD 6 Â±1 day . Males females least 18 year age old 65 year age time informed consent . Patient / Legally Authorized Representative ( LAR ) voluntarily agree provide write informed consent willingness ability comply aspects protocol . Patients electrical chemical burn . Patients study burn site excise `` graft '' Integra . Patients study burn site buttock , scalp , hand , foot , neck ear . Patients take vasopressor inotropes . Patients use systemic immunosuppressant ( e.g. , corticosteroid antineoplastic agent , etc. ) . Patients acute renal failure , define creatinine clearance ( CrCL ) &gt; 2.5 mg/dL AKIN score great equal 2 estimate GFR &lt; 30 , assessment conduct part patient 's routine clinical care . Patients acute respiratory distress syndrome ( ARDS ) , assessment conduct part patient 's routine clinical care . Patients liver cirrhosis ( ChildsPugh B Class great ) AST / ALT level great equal 2 time upper limit theinstitution 's normal range , assessment conduct part patient 's routine clinical care . Patients known sensitivity know intolerance mafenide acetate ( Sulfamylon ) silver . Patients concurrent medical condition , opinion investigator , may compromise safety objective study . Patients breastfeed , pregnant expect become pregnant study.. Patients expose investigational drug device within 30 day prior Screening schedule receive another investigational drug device either Treatment Phase Followup Evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>